[go: up one dir, main page]

MXPA04005992A - Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa. - Google Patents

Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.

Info

Publication number
MXPA04005992A
MXPA04005992A MXPA04005992A MXPA04005992A MXPA04005992A MX PA04005992 A MXPA04005992 A MX PA04005992A MX PA04005992 A MXPA04005992 A MX PA04005992A MX PA04005992 A MXPA04005992 A MX PA04005992A MX PA04005992 A MXPA04005992 A MX PA04005992A
Authority
MX
Mexico
Prior art keywords
molecule
modified
therapeut
nucleic acid
acid encoding
Prior art date
Application number
MXPA04005992A
Other languages
English (en)
Inventor
Holm Patrik
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04005992A publication Critical patent/MXPA04005992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La invencion se refiere a un compuesto de la formula I(ver formula I) en donde R1 representa cloro, fluoro hidroxil asi como isomeros opticos y racematos del mismo, y tambien sales, profarmacos, solvatos y formas cristalinas farmaceuticamente aceptables del mismo, a un procedimiento para preparar estos compuestos, a su utilidad para tratar condiciones clinicas que incluyen trastornos de lipidos (dislipidemias) ya sea que esten asociados o no con resistencia a insulina, a metodos para su uso terapeutico y a composiciones farmaceuticas que los contienen.
MXPA04005992A 2001-12-19 2002-12-18 Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa. MXPA04005992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0104333A SE0104333D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents
PCT/GB2002/005743 WO2003051826A1 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha

Publications (1)

Publication Number Publication Date
MXPA04005992A true MXPA04005992A (es) 2004-09-27

Family

ID=20286432

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005992A MXPA04005992A (es) 2001-12-19 2002-12-18 Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.

Country Status (26)

Country Link
US (1) US7276539B2 (es)
EP (1) EP1458677B1 (es)
JP (2) JP3810770B2 (es)
KR (1) KR20040068589A (es)
CN (1) CN100343229C (es)
AR (1) AR038046A1 (es)
AT (1) ATE428691T1 (es)
AU (1) AU2002352426A1 (es)
BR (1) BR0215090A (es)
CA (1) CA2470066C (es)
CO (1) CO5590908A2 (es)
DE (1) DE60232018D1 (es)
ES (1) ES2324025T3 (es)
HU (1) HUP0402093A3 (es)
IL (1) IL162378A0 (es)
IS (1) IS7303A (es)
MX (1) MXPA04005992A (es)
NO (1) NO20043084L (es)
NZ (1) NZ533365A (es)
PL (1) PL370623A1 (es)
RU (1) RU2004117776A (es)
SE (1) SE0104333D0 (es)
TW (1) TW200410678A (es)
UA (1) UA80407C2 (es)
WO (1) WO2003051826A1 (es)
ZA (1) ZA200404585B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489834C (en) 2002-06-20 2006-10-03 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0427524D0 (en) * 2004-12-16 2005-01-19 Astrazeneca Ab Chemical process
GB0427701D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Therapeutic agents
PL2125711T3 (pl) 2007-03-08 2014-05-30 Albireo Ab Pochodne kwasy 3-fenylopropionowego oraz ich zastosowanie w leczeniu nieswoistego zapalenia jelit

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
AU1903799A (en) 1997-12-05 1999-06-28 Eisai Co. Ltd. Compositions and methods for modulating the activity of fibroblast growth factor
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801990D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
RU2267484C2 (ru) * 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
SE9904421D0 (sv) 1999-12-03 1999-12-03 Astra Ab New compounds
TW574193B (en) 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
JP2004500389A (ja) 2000-03-09 2004-01-08 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒメディエーターの治療での使用
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
SE0101978D0 (sv) 2001-06-01 2001-06-01 Astrazeneca Ab New compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
ES2278045T3 (es) 2001-09-08 2007-08-01 Astrazeneca Ab Derivados benzotiazepinicos y benzotiadiazepinicos con actividad inhibidora del transporte de acidos biliares del ileon (ibat) para el tratamiento de hiperlipidemia.
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
CA2489834C (en) 2002-06-20 2006-10-03 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
SE0201936D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314078D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
CN100343229C (zh) 2007-10-17
ZA200404585B (en) 2005-10-26
TW200410678A (en) 2004-07-01
DE60232018D1 (de) 2009-05-28
ES2324025T3 (es) 2009-07-29
NO20043084L (no) 2004-07-16
HK1068866A1 (en) 2005-05-06
BR0215090A (pt) 2004-11-16
CA2470066C (en) 2007-04-10
SE0104333D0 (sv) 2001-12-19
EP1458677A1 (en) 2004-09-22
JP3810770B2 (ja) 2006-08-16
ATE428691T1 (de) 2009-05-15
NZ533365A (en) 2006-05-26
US7276539B2 (en) 2007-10-02
US20050215630A1 (en) 2005-09-29
IL162378A0 (en) 2005-11-20
JP2006241162A (ja) 2006-09-14
CA2470066A1 (en) 2003-06-26
HUP0402093A2 (hu) 2005-02-28
CO5590908A2 (es) 2005-12-30
JP2005511785A (ja) 2005-04-28
CN1620430A (zh) 2005-05-25
IS7303A (is) 2004-06-08
RU2004117776A (ru) 2006-01-10
EP1458677B1 (en) 2009-04-15
AR038046A1 (es) 2004-12-22
HUP0402093A3 (en) 2008-08-28
WO2003051826A1 (en) 2003-06-26
AU2002352426A1 (en) 2003-06-30
PL370623A1 (en) 2005-05-30
UA80407C2 (en) 2007-09-25
KR20040068589A (ko) 2004-07-31

Similar Documents

Publication Publication Date Title
DK2014678T3 (da) KDR-peptider og vacciner indeholdende disse
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
WO2005005462A3 (en) Blys antagonists and uses thereof
MXPA03002572A (es) Secuencias de nucleotidos que intervienen en la fertilidad de los machos y metodo de su uso.
TW200635946A (en) Binding proteins specific for human matriptase
MXPA04005992A (es) Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.
EP1100815A4 (en) PROTEASE TYPE II CLEAVABLE PEPTIDE
DE60239729D1 (de) Männliche fertilitätvermittelnde nukleotidsequenzen und deren verwendung
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
DK1536006T3 (da) Cancerantigener og anvendelse deraf
WO2002102852A3 (en) Modified cd8 molecule, nucleic acid encoding said molecule, and their therapeut ic use
GB0418388D0 (en) Cell therapy
IL149416A0 (en) Human enzymes of the metalloprotease family
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
ATE291621T1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
WO2001066752A3 (en) Reproduction-specific genes
WO2005000870A3 (en) Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof
SG161106A1 (en) Inhibitor proteins of a protease and use thereof
WO2003066879A3 (en) Amino acid transporters
FR2792651B1 (fr) Sequence genomique et polypeptides de pyrococcus abyssi, leurs fragments et leurs utilisations
DK0811068T3 (da) Humane DNase I varianter
KR20040053279A (ko) 스트레스 저항성 및 내성 단백질을 코딩하는 유전자
EP1191096A4 (en) NEW PROTEIN AND ITS DNA
WO2005060667A3 (en) Nucleic acid and amino acid sequences involved in pain
WO2004078776A3 (en) Ny-eso-1 peptides which bind to class ii molecules and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal